IA
ELDN icon

IFP Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

IFP Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32 Sell
8
-3
-27% -$11 ﹤0.01% 5049
2026
Q1 		$34 Buy
+11
New +$26 ﹤0.01% 4877
2023
Q1 		– Sell
-1
Closed -$1K – 3676
2022
Q4 		$1K Hold
1
– – ﹤0.01% 4327
2022
Q3 		$1K Hold
1
– – ﹤0.01% 4539
2022
Q2 		$1K Hold
1
– – ﹤0.01% 4317
2022
Q1 		$1K Buy
+1
New +$4 ﹤0.01% 4317
2017
Q4 		– Sell
-2
Closed – – 3877
2017
Q3 		$0 Hold
2
– – ﹤0.01% 4099
2017
Q2 		$0 Hold
2
– – ﹤0.01% 4106
2017
Q1 		$0 Hold
2
– – ﹤0.01% 4024
2016
Q4 		$0 Sell
2
-15
-88% -$2.87K ﹤0.01% 4012
2016
Q3 		$4K Buy
17
+15
+750% +$5.49K ﹤0.01% 3313
2016
Q2 		$1K Buy
+2
New +$2.21K ﹤0.01% 3599
2016
Q1 		– Sell
-2
Closed -$2K – 2646
2015
Q4 		$2K Buy
+2
New +$3.48K ﹤0.01% 3311

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

IFP Advisors's ELDN Position: Q2 2026 in Review

IFP Advisors reduced its Eledon Pharmaceuticals (ELDN) stake by 27% in Q2 2026, selling an estimated $11 and leaving 8 shares worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #5049.

IFP Advisors first reported a position in ELDN in Q4 2015 and has held it in 13 quarters since. The position peaked at $4K in Q3 2016. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • IFP Advisors held 8 shares of Eledon Pharmaceuticals worth $32 as of Q2 2026.
  • IFP Advisors sold 3 Eledon Pharmaceuticals shares in Q2 2026, an estimated $11.
  • Eledon Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5049 holding.
  • IFP Advisors first reported a position in Eledon Pharmaceuticals in Q4 2015 and has held it in 13 quarters since.
  • IFP Advisors's Eledon Pharmaceuticals position peaked at $4K in Q3 2016.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.